| 1 |
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
Julie Renee Brahmer et al. · New England Journal of Medicine
Open access |
31 May 2015 |
8,632 |
| 2 |
Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma
Robert John Motzer, Thomas E. Hutson, Piotr Tomczak et al. · New England Journal of Medicine
Open access |
10 Jan 2007 |
5,801 |
| 3 |
Sorafenib in Advanced Clear-Cell Renal-Cell Carcinoma
Bernard J. Escudier, Tim G Eisen, Walter Michael Stadler et al. · New England Journal of Medicine
Open access |
10 Jan 2007 |
4,813 |
| 4 |
Temsirolimus, Interferon Alfa, or Both for Advanced Renal-Cell Carcinoma
Gary R. Hudes, Michael Anthony Carducci, Piotr Tomczak et al. · New England Journal of Medicine
|
30 May 2007 |
3,671 |
| 5 |
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
Leora Horn et al. · New England Journal of Medicine
Open access |
25 Sep 2018 |
3,637 |
| 6 |
Lapatinib plus Capecitabine for HER2-Positive Advanced Breast Cancer
Charles E. Geyer, John Forster, Deborah L. Lindquist et al. · New England Journal of Medicine
Open access |
27 Dec 2006 |
3,486 |
| 7 |
Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden
Matthew David Hellmann et al. · New England Journal of Medicine
Open access |
16 Apr 2018 |
3,185 |
| 8 |
First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial
Yelena Yuriy Janjigian et al. · The Lancet
Open access |
5 Jun 2021 |
3,110 |
| 9 |
Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
José Baselga, Javier Cortés, Sung‐Bae Kim et al. · New England Journal of Medicine
Open access |
7 Dec 2011 |
2,559 |
| 10 |
Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial
Luca Gianni, Tadeusz Pieńkowski, Young‐Hyuck Im et al. · The Lancet Oncology
|
10 Dec 2011 |
2,403 |
| 11 |
Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial
Charles S. Fuchs et al. · The Lancet
Open access |
2 Oct 2013 |
2,223 |
| 12 |
Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma
Michael Wang et al. · New England Journal of Medicine
Open access |
19 Jun 2013 |
1,710 |
| 13 |
Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial
Edward B. Garon et al. · The Lancet
Open access |
2 Jun 2014 |
1,321 |
| 14 |
Sorafenib for Treatment of Renal Cell Carcinoma: Final Efficacy and Safety Results of the Phase III Treatment Approaches in Renal Cancer Global Evaluation Trial
Bernard J. Escudier, Tim G Eisen, Walter Michael Stadler et al. · Journal of Clinical Oncology
Open access |
18 May 2009 |
1,089 |
| 15 |
Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial
Robert John Motzer, Thomas E. Hutson, Hilary Glen et al. · The Lancet Oncology
Open access |
25 Oct 2015 |
957 |
| 16 |
A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses
David Cameron et al. · Breast Cancer Research and Treatment
|
10 Jan 2008 |
810 |
| 17 |
Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma after Nephrectomy
Alain Ravaud et al. · New England Journal of Medicine
|
10 Oct 2016 |
791 |
| 18 |
Long‐term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors
Lee S. Rosen, David Gordon, Nerses Simon Tchekmedyian et al. · Cancer
Open access |
6 May 2004 |
719 |
| 19 |
5-year results of accelerated partial breast irradiation using sole interstitial multicatheter brachytherapy versus whole-breast irradiation with boost after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: a randomised, phase 3, non-inferiority trial
Vratislav Strnad et al. · The Lancet
|
23 Oct 2015 |
662 |
| 20 |
Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma
Yuichiro� Doki et al. · UCL Discovery (University College London)
Open access |
3 Feb 2022 |
532 |
| 21 |
Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial
Oliver A. Sartor et al. · The Lancet Oncology
|
13 May 2014 |
499 |
| 22 |
Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial
Alessandro Gronchi et al. · The Lancet Oncology
|
9 May 2017 |
498 |
| 23 |
Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer
Kohei Shitara et al. · Nature
Open access |
23 Mar 2022 |
455 |
| 24 |
Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study
Lecia Van Dam Sequist, Ji‐Youn Han, Myung‐Ju Ahn et al. · The Lancet Oncology
Open access |
3 Feb 2020 |
425 |
| 25 |
Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results
Michael Wang et al. · Blood
Open access |
9 Jun 2015 |
412 |
| 26 |
Reliability and validity of the Gastrointestinal Symptom Rating Scale (GSRS) and Quality of Life in Reflux and Dyspepsia (QOLRAD) questionnaire in dyspepsia: A six-country study
Károly R Kulich, Ahmed Madisch, Franco Pacini et al. · Health and Quality of Life Outcomes
Open access |
2008 |
407 |
| 27 |
Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): an open-label, randomised, phase 3 study
Fabrice Barlési, Johan Vansteenkiste, David Robert Spigel et al. · The Lancet Oncology
|
24 Sep 2018 |
400 |
| 28 |
Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled analysis
Scott Joseph Antonia, Hossein Borghaei, Suresh S. Ramalingam et al. · The Lancet Oncology
Open access |
14 Aug 2019 |
373 |
| 29 |
Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trial
Thomas C. C. Yau et al. · The Lancet
Open access |
May 2025 |
353 |
| 30 |
Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I–III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial
Gustavo Ismael, Roberto Hegg, Susanne Muehlbauer et al. · The Lancet Oncology
|
8 Aug 2012 |
352 |
| 31 |
Open-Label, Single-Arm, Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Non–Clear Cell Renal Cell Carcinoma
David F. McDermott, Jae‐Lyun Lee, Marek Ziobro et al. · Journal of Clinical Oncology
Open access |
2 Feb 2021 |
292 |
| 32 |
Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomised trial
Ian F. Tannock et al. · The Lancet Oncology
|
3 Jun 2013 |
289 |
| 33 |
Neoadjuvant Chemotherapy in High-Risk Soft Tissue Sarcomas: Final Results of a Randomized Trial From Italian (ISG), Spanish (GEIS), French (FSG), and Polish (PSG) Sarcoma Groups
Alessandro Gronchi et al. · Journal of Clinical Oncology
Open access |
18 May 2020 |
264 |
| 34 |
Late side-effects and cosmetic results of accelerated partial breast irradiation with interstitial brachytherapy versus whole-breast irradiation after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: 5-year results of a randomised, controlled, phase 3 trial
Csaba Polgár et al. · The Lancet Oncology
|
13 Jan 2017 |
259 |
| 35 |
CEREBEL (EGF111438): A Phase III, Randomized, Open-Label Study of Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer
Xavier B. Pivot et al. · Journal of Clinical Oncology
Open access |
21 Jan 2015 |
254 |
| 36 |
A Phase II Trial of the Multitargeted Tyrosine Kinase Inhibitor Lenvatinib (E7080) in Advanced Medullary Thyroid Cancer
Martin Jean Schlumberger, Barbara Jarząb, Maria E. Cabanillas et al. · Clinical Cancer Research
Open access |
26 Aug 2015 |
251 |
| 37 |
First-Line Nivolumab Plus Chemotherapy for Advanced Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma: 3-Year Follow-Up of the Phase III CheckMate 649 Trial
Yelena Yuriy Janjigian et al. · Journal of Clinical Oncology
Open access |
21 Feb 2024 |
246 |
| 38 |
Radical mastectomy versus radical mastectomy plus internal mammary dissection. Five-year results of an international cooperative study
J.‐P. Lacour, P. Bucalossi, E. Cacers et al. · Cancer
Open access |
1976 |
237 |
| 39 |
Adjuvant Sunitinib for High-risk Renal Cell Carcinoma After Nephrectomy: Subgroup Analyses and Updated Overall Survival Results
Robert John Motzer et al. · European Urology
Open access |
28 Sep 2017 |
228 |
| 40 |
Trastuzumab deruxtecan in HER2-positive advanced breast cancer with or without brain metastases: a phase 3b/4 trial
Nadia Harbeck et al. · Nature Medicine
Open access |
13 Sep 2024 |
216 |
| 41 |
A Phase II Study of Tg4010 (Mva-Muc1-Il2) in Association with Chemotherapy in Patients with Stage III/IV Non-small Cell Lung Cancer
Rodryg Ramlau, Élisabeth Quoix, Janusz Rolski et al. · Journal of Thoracic Oncology
Open access |
Jul 2008 |
207 |
| 42 |
LBA6_PR Nivolumab (nivo) plus chemotherapy (chemo) versus chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer (GC/GEJC)/esophageal adenocarcinoma (EAC): First results of the CheckMate 649 study
Markus Hermann Moehler, Kohei Shitara, Marcelo Garrido et al. · Annals of Oncology
Open access |
Sep 2020 |
206 |
| 43 |
An open randomised trial of second-line endocrine therapy in advanced breast cancer
Carsten Rose, O. Vtoraya, Anna Pluzanska et al. · European Journal of Cancer
|
16 Sep 2003 |
193 |
| 44 |
A phase II study of vinflunine in bladder cancer patients progressing after first-line platinum-containing regimen
Stéphane Culine, Christine Théodore, Maria De Santis et al. · British Journal of Cancer
Open access |
18 Apr 2006 |
186 |
| 45 |
Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection plus chemotherapy in HER2-positive early breast cancer (FeDeriCa): a randomised, open-label, multicentre, non-inferiority, phase 3 study
Antoinette R. Tan, Seock‐Ah Im, André P. L. Mattar et al. · The Lancet Oncology
|
21 Dec 2020 |
175 |
| 46 |
Panitumumab plus radiotherapy versus chemoradiotherapy in patients with unresected, locally advanced squamous-cell carcinoma of the head and neck (CONCERT-2): a randomised, controlled, open-label phase 2 trial
J. Giralt, José Manuel Trigo, Sandra Nuyts et al. · The Lancet Oncology
|
14 Jan 2015 |
174 |
| 47 |
Fulvestrant 500 mg versus anastrozole 1 mg for the first-line treatment of advanced breast cancer: follow-up analysis from the randomized ‘FIRST’ study
John F.R. Robertson, Justin P.O. Lindemann, Antonio Llombart‐Cussac et al. · Breast Cancer Research and Treatment
|
12 Oct 2012 |
172 |
| 48 |
A randomized trial to study first-line combination therapy with or without a protease inhibitor in HIV-1-infected patients
Remko van Leeuwen et al. · AIDS
|
17 Apr 2003 |
171 |
| 49 |
Chemoradiotherapy with or without panitumumab in patients with unresected, locally advanced squamous-cell carcinoma of the head and neck (CONCERT-1): a randomised, controlled, open-label phase 2 trial
Ricard Mesı́a, Michael Henke, A. Fortin et al. · The Lancet Oncology
|
14 Jan 2015 |
164 |
| 50 |
Biomarker results from the AVADO phase 3 trial of first-line bevacizumab plus docetaxel for HER2-negative metastatic breast cancer
D.W. Miles, Sanne Lysbet de Haas, Luc Yves Dirix et al. · British Journal of Cancer
Open access |
19 Feb 2013 |
157 |